Erythropoietin (Epogen) therapy primarily stimulates:

• A. Stimulates white blood cell production
• B. Stimulates red blood cell production
• C. Increases platelet aggregation
• D. Decreases anemia by iron absorption

Answer: (B)

Erythropoietin stimulates the production of red blood cells. Epogen is a recombinant form of this hormone and is given to treat anemia by signaling the bone marrow to increase erythropoiesis. It acts on erythroid progenitor cells in the bone marrow, promoting their maturation into mature red blood cells, which raises hemoglobin and hematocrit levels. This is why the therapy’s primary effect is increasing red blood cell production, helping to lessen anemia.

Iron status matters because you need adequate iron stores for the new red cells to form. If iron is deficient, the response to Epogen will be limited, so iron supplementation may be needed to maximize effectiveness. Epogen therapy is commonly used for anemia associated with chronic kidney disease or chemotherapy, but it can raise blood viscosity if overused, so monitoring hemoglobin/hematocrit and blood pressure is important.

Stimulation of white blood cells or platelets isn’t the effect of erythropoietin—those lines of production are driven by other factors. And erythropoietin doesn’t directly increase iron absorption; it enhances red cell production when iron is available.